On Tuesday, Moderna suggested the US Food and Drug Administration should approve booster doses of its COVID-19 vaccine in fully immunised older adults and other high-risk persons.

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year | Business Wire

The evidence supports the public health advantage of a booster dose of the vaccine to restore immune response while reducing the number of "breakthrough" infections in fully vaccinated people, according to the company.

Moderna's comments were made public in briefing documents released ahead of an FDA meeting of outside expert advisers on Thursday to examine the booster dose.